Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Relationship between ABO blood group distribution and clinical characteristics in patients with COVID-19

Yuqin Wu a,1, Zhicai Fengb,1, Peng Lia, Qizhi Yu a,⁎

a Department of Radiology, The First Hospital of Changsha, Changsha, Hunan 410011, China
b Department of Nephrology, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China

ARTICLE INFO

Keywords:
COVID-19
ABO blood group
Clinical characteristics

ABSTRACT

Objective: To explore ABO blood group distribution and clinical characteristics in patients with COVID-19.
Methods: The clinical data of 187 patients with COVID-19 seen between January 20, 2020 and March 5, 2020 at the First Hospital of Changsha were retrospectively analyzed. The differences in the ABO blood group distribution between COVID-19 patients and the control group (1991 cases) were analyzed. The relationship between blood type and clinical characteristics was analyzed.
Results: Of the 187 patients with COVID-19, 69 had type A (36.90%), 63 had type B (33.69%), 41 had type O (21.92%), and 14 had type AB blood (7.49%). The proportion of patients with type A blood in the COVID-19 group was significantly higher than that in the control group (36.90% vs. 27.47%, P = 0.006), while the proportion of patients with type O blood in the COVID-19 group was significantly lower than that in the control group (21.92% vs. 30.19%, P = 0.018). The risk of COVID-19 was higher for individuals with blood group A than for those with blood group O (OR = 1.849, 95% CI = 1.228–2.768, P = 0.003). The risk of COVID-19 was higher for patients with blood group A than for those with a blood group other than A (OR = 1.544, 95% CI = 1.122–2.104, P = 0.006). Patients with blood group O had a lower risk of COVID-19 than non-O blood group patients (OR = 0.649, 95% CI = 0.457–0.927, P = 0.018). The ABO blood group distribution was related to COVID-19 status.
Conclusions: Patients with blood group A had an increased risk for infection with SARS-CoV-2, whereas blood group O was associated with a decreased risk, indicating that certain ABO blood groups were correlated with SARS-CoV-2 susceptibility. Blood type was related to some clinical characteristics of patients with COVID-19.

1. Introduction

Since December 2019, many cases of pneumonia caused by the novel coronavirus have been discovered in Wuhan, Hubei Province. The disease has been officially named coronavirus disease 2019 (COVID-19) by the WHO [1]. With the spread of the disease, many cases have been found in other parts of China and abroad [2]. The novel coronavirus is related to the viruses that cause the deadly diseases severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) [3]. Huang et al. [4] first reported 41 COVID-19 cases, most of which had been contracted at the Huanan Seafood Market. The clinical manifestations included fever, cough, dyspnea, myalgia, fatigue, a normal or decreased white blood cell count, and evidence of pneumonia on imaging. Scholars at home and abroad have conducted research on the association between blood groups and viruses and found that blood groups show associations with certain viral infections. Scholars at home and abroad have reported the association of blood type with rotavirus, noroviruses (NoVs), dengue virus, Norwalk virus and hepatitis B virus [5–8]. The human blood type has been used as a genetic marker. By studying the relationship of human blood type with virus infection, it is possible to determine the susceptibility to the virus of people with different blood types. We collected samples from 187 COVID-19 patients at the First Hospital of Changsha for this article, analyzed the ABO blood group distribution, and compared the ABO blood group distribution of the patient group with that of the control group. Then, we explored the ABO blood group distribution and clinical characteristics of COVID-19 patients.
2. Methods

2.1. Data sources

The medical records of patients were analyzed by the research team of the Third Xiangya Hospital of Central South University and the First Hospital of Changsha. Data on clinical characteristics were obtained with data collection forms from electronic medical records. The data were reviewed by a trained team of physicians.

2.2. Study design

This was a retrospective case-control study. The medical records of 187 patients with COVID-19 were divided into 4 groups, A, B, O, and AB, according to different ABO blood types. The ABO blood group distribution of the 187 patients was analyzed and compared with the ABO blood group distribution of the control group. The general conditions and clinical characteristics of 187 patients with COVID-19 were analyzed.

The ABO type of each patient was retrieved from the ABO blood type database. Therefore, the case group consisted of Han Chinese individuals with known blood types who had received a diagnosis of COVID-19 and who were hospitalized in or discharged from The First Hospital of Changsha between January 20, 2020 and March 5, 2020. The control group consisted of all non-COVID-19 Han Chinese patients with determined blood types who were hospitalized between January 2019 and February 2020; for subjects with multiple admissions, only the first was considered.

The study was approved by the Ethical Committee of The First Hospital of Changsha. Due to the retrospective nature of the study and because no identifying information relating to participants was included, written informed consent was waived. All experimental protocols were conducted according to the Strengthening of the Reporting of Observational Studies in Epidemiology guidelines.

2.3. Statistical analysis

Statistical computations were performed using GraphPad Prism 7. Data were analyzed with the $\chi^2$ test and Fisher’s exact test. ORs with 95% CIs for specific blood types in COVID-19 patients were assessed with logistic regression models. $P < 0.05$ was considered statistically significant.

3. Results

3.1. Comparison of the ABO blood group distribution of 187 patients with COVID-19 and the blood group distribution of the control group

The ABO blood group distribution of 187 patients with COVID-19 revealed that there were 69 patients with type A blood (36.90%), 63 patients with type B (33.69%), 41 patients with type O (21.92%), and 14 patients with type AB (7.49%). Among the blood types, type A was the most common, and type AB was the least common (Table 1). The COVID-19 patient group contained higher percentages of individuals with type A and B blood than the control group. The proportion of patients with COVID-19 with type A blood was significantly higher than the proportion of controls (36.90% vs. 27.47%, $P = 0.006$), while the proportion of patients with COVID-19 with type O blood was significantly lower than the proportion of controls (21.92% vs. 30.19%, $P = 0.018$). The risk of COVID-19 was higher in patients with blood group A than in those with blood group O (OR = 1.849, 95% CI = 1.228-2.768, $P = 0.003$). The risk of COVID-19 was higher in patients with blood group A than in those with other blood groups (OR = 1.544, 95% CI = 1.122-2.104, $P = 0.006$). Patients with blood group O had a lower risk of COVID-19 than patients with other blood group types (OR = 0.649, 95% CI = 0.457-0.927, $P = 0.018$).

By analyzing 187 patients with COVID-19, we found a correlation between the ABO blood group distribution and fever. In terms of symptom distribution, fever was more common in patients with certain blood types (patients with fever had type A (85.51%), type B (76.19%), type O (53.66%), and type AB blood (57.14%), $P = 0.002$). The ABO blood group distribution was also related to cough. In terms of the symptom distribution, cough was associated with certain blood types (patients with cough had type A (71.01%), B (57.14%), O (43.90%), and AB blood (71.43%), $P = 0.031$).

The ABO blood group distribution was significantly related to dyspnea. Patients with type A, B, and O blood were less likely to present with dyspnea [patients with dyspnea had type A (42.03%), type B (15.87%), type O (31.71%), and type AB blood (50.00%), $P = 0.005$]. The ABO blood group distribution was also related to sore throat. Patients with all blood types were less likely to present with sore throat [patients with sore throat had type A (33.33%), B (7.94%), type O (29.27%), and type AB blood (21.43%), $P = 0.004$]. The ABO blood group distribution was significantly related to fatigue. Patients with type A and O blood were more likely to present with fatigue [patients with fatigue had type A (60.87%), type B (47.62%), type O (56.10%), and type AB blood (14.29%), $P = 0.012$]. There was no significant difference between the patients in different blood groups ($P > 0.05$) (Table 2).

4. Discussion

The ABO blood group system mainly involves the A and B antigens and their corresponding antibodies. The antigen-encoding gene is located on chromosome 9q34.1-34.2. It consists of the A, B, and O alleles, and there are a total of 4 genetic phenotypes (A, B, O, and AB blood types) [9,10]. Differences in blood group antigen expression can increase or decrease host susceptibility to many infections. Blood group antigens can play a direct role in infection by serving as receptors and/or coreceptors for microorganisms, parasites, and viruses. In addition, many blood group antigens facilitate intracellular uptake, signal transduction, or cell adhesion through the organization of membrane microdomains. Blood group antigens can modify the innate immune
antibody, in the blood. However, there might be other mechanisms that require further study.

In this study, we found that the ABO blood group distribution was related to fever, cough, dyspnea, sore throat, chest pain/distress and fatigue. There were no significant differences between the other blood group patient groups ($P > 0.05$). This indicated that blood type might have some influence on the clinical characteristics of patients with COVID-19. The clinical manifestations of people with different blood types after infection with COVID-19 were different.

This study had some limitations. First, the vast majority of patients diagnosed with COVID-19 were not tested to determine their blood group. We retested the patients who were not previously tested. Only 187 patients with undiagnosed COVID-19 could have been enrolled in the control group, and the study lacked a normal population group as a control. In summary, the blood group of individuals might not be one of the risk factors for COVID-19, but it was related to the clinical characteristics of patients with COVID-19.

**Informed consent**

Written informed consent was obtained from all subjects (patients) in this study.

**Ethical approval**

Institutional Review Board approval was obtained.

**Funding**

The authors state that this work has not received any funding.

**CRediT authorship contribution statement**

Yugín Wu: Data curation, Writing - original draft. Zhici Feng: Writing - review & editing. Peng Li: Investigation. Qizhi Yu: Conceptualization, Methodology.

**Declaration of Competing Interest**

The authors declare that there is no conflict of interest or financial disclosure related to this publication.

**References**

[1] J. Gao, Z. Tian, X. Yang. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, BioSci. Trends 14 (1) (2020) 72–73.
[2] C. Wang, P.W. Horby, F.G. Hayden, G.F. Gao, A novel coronavirus outbreak of global health concern, Lancet (London, England) 395 (10223) (2020) 470–473.
[3] Y. Yin, R.G. Wunderink, MERS, SARS and other coronaviruses as causes of pneumonia, Respiriology (Carlton, Vic) 23 (2) (2018) 130–137.
[4] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet (London, England) 395 (10223) (2020) 497–506.
[5] S. Kalayanarooj, R.V. Gibbons, D. Vaughn, S. Green, A. Nisalak, R.J. Garman, M.P. Mammen Jr., G.C. Perng, Blood group AB is associated with increased risk for severe dengue disease in secondary infections, J. Infect. Dis. 195 (7) (2007) 1014–1017.
[6] E.P. Hennessy, A.D. Green, M.P. Connor, R. Darby, P. MacIntordal, Norwalk virus infection and disease is associated with ABO histo-blood group type, J. Infect. Dis. 188 (1) (2003) 176–177.
[7] A.M. Kazi, M.M. Cortese, Y. Yu, B. Lopman, A.L. Morrow, J.A. Fleming, M.M. McNeal, A.D. Steele, U.D. Parashar, A.K.M. Zaidi, et al., Secretor and salivary ABO blood group antigen status predict rotavirus vaccine take in infants, J. Infect. Dis. 215 (5) (2017) 786–789.
[8] J. Liu, S. Zhang, M. Liu, Q. Wang, H. Shen, Y. Zhang, Distribution of ABO/Rh blood groups and their association with hepatitis B virus infection in 3.8 million Chinese adults: a population-based cross-sectional study, J Viral Hepat. 25 (4) (2018) 401–411.

---

**Table 2** Relationship between the ABO blood group distribution and clinical characteristics in patients with COVID-19 pneumonia (n [%]).

| Factor                  | ABO blood group | $\chi^2$ | P   |
|-------------------------|-----------------|----------|-----|
|                         | A               | B        | O   | AB  |
| Age                     |                 |          |     |     |
| < 40                    | 22 (31.88)      | 25 (39.68) | 14 (34.15) | 8 (57.14) | 3.553 | 0.314 |
| ≥ 40                    | 47 (68.12)      | 38 (60.32) | 27 (65.85) | 6 (42.86) |
| Gender                  |                 |          |     |     |
| Male                    | 35 (50.72)      | 33 (52.38) | 22 (53.66) | 7 (50.00) | 0.115 | 0.990 |
| Female                  | 34 (49.28)      | 30 (47.62) | 19 (46.34) | 7 (50.00) |
| Fever                   |                 |          |     |     |
| Yes                     | 59 (85.51)      | 48 (76.19) | 22 (53.66) | 8 (57.14) | 15.460 | 0.002* |
| No                      | 10 (14.49)      | 15 (23.81) | 19 (46.34) | 6 (28.56) |
| Cough                   |                 |          |     |     |
| Yes                     | 49 (71.01)      | 36 (57.14) | 18 (43.90) | 10 (71.43) | 8.909 | 0.031* |
| No                      | 20 (28.99)      | 27 (42.86) | 23 (56.10) | 6 (28.57) |
| Sputum production       |                 |          |     |     |
| Yes                     | 17 (24.64)      | 14 (22.22) | 17 (41.46) | 5 (35.71) | 5.478 | 0.140 |
| No                      | 52 (75.36)      | 49 (77.78) | 24 (58.54) | 9 (64.29) |
| Dyspnoea                |                 |          |     |     |
| Yes                     | 29 (42.03)      | 10 (15.87) | 13 (31.71) | 7 (50.00) | 12.890 | 0.005* |
| No                      | 40 (57.97)      | 53 (84.13) | 26 (68.29) | 7 (50.00) |
| Myalgia or fatigue      |                 |          |     |     |
| Yes                     | 14 (20.29)      | 7 (11.11)  | 3 (7.32) | 3 (21.43) | 4.714 | 0.194 |
| No                      | 55 (79.71)      | 56 (88.89) | 9 (22.68) | 11 (78.57) |
| Headache                |                 |          |     |     |
| Yes                     | 13 (18.84)      | 16 (25.40) | 4 (9.75) | 2 (14.29) | 4.193 | 0.241 |
| No                      | 56 (81.16)      | 47 (74.60) | 37 (90.24) | 12 (85.71) |
| Sore throat             |                 |          |     |     |
| Yes                     | 23 (33.33)      | 5 (7.94)  | 12 (29.27) | 3 (21.43) | 13.160 | 0.004* |
| No                      | 46 (66.67)      | 58 (92.06) | 29 (70.73) | 12 (85.71) |
| Chest pain or chest distress |             |          |     |     |
| Yes                     | 11 (15.94)      | 9 (14.29)  | 3 (7.32) | 5 (35.71) | 6.693 | 0.082 |
| No                      | 58 (84.06)      | 54 (85.71) | 9 (22.68) | 6 (42.94) |
| Fatigue                 |                 |          |     |     |
| Yes                     | 42 (60.87)      | 30 (47.62) | 23 (56.10) | 2 (14.29) | 10.910 | 0.012* |
| No                      | 27 (39.13)      | 33 (52.38) | 18 (43.90) | 12 (85.71) |
| chronic underlying diseases |             |          |     |     |
| Yes                     | 33 (47.83)      | 23 (34.92) | 18 (43.90) | 5 (35.71) | 2.544 | 0.467 |
| No                      | 36 (52.17)      | 41 (65.08) | 23 (56.10) | 9 (64.29) |

Data are n (%) unless specified otherwise. COVID-19 = Coronavirus disease 2019. * Means the result have statistically significance.
[9] S.K. Vasan, K. Rostgaard, A. Majeed, H. Ullum, K.E. Titlestad, O.B. Pedersen, C. Erikstrup, K.R. Nielsen, M. Melbye, O. Nyren, et al., ABO blood group and risk of thromboembolic and arterial disease: a study of 1.5 million blood donors, Circulation 133 (15) (2016) 1449–1457 discussion 1457.

[10] L. Amundadottir, P. Kraft, R.Z. Stolzenberg-Solomon, C.S. Fuchs, G.M. Petersen, A.A. Arslan, H.B. Bueno-de-Mesquita, M. Gross, K. Helzlsouer, E.J. Jacobs, et al., Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer, Nat. Genet. 41 (9) (2009) 986–990.

[11] L. Cooling, Blood Groups in Infection and Host Susceptibility, Clin. Microbiol. Rev. 28 (3) (2015) 801–870.

[12] Z. Kaidarova, M.D. Bravo, H.T. Kamel, B.S. Custer, M.P. Busch, M.C. Lanteri, Blood group A and D negativity are associated with symptomatic West Nile virus infection, Transfusion 56 (7) (2016) 1699–1706.

[13] S. Sharma, M. Hagbom, B. Carlsson, J. Nederby Ohld, M. Insulander, R. Eriksson, M. Simonsson, M. Widerstrom, J. Nordgren, Secretor status is associated with susceptibility to disease in a large GII.6 Norovirus foodborne outbreak, Food Environ. Virol. 12 (1) (2020) 28–34.

[14] R. Perez-Ortin, S. Vila-Vicente, N. Carmona-Vicente, C. Santiso-Bellon, J. Rodriguez-Diaz, J. Buesa, Histo-blood group antigens in children with symptomatic rotavirus infection, Viruses 11 (4) (2019).

[15] Y. Cheng, G. Cheng, C.H. Chui, F.Y. Lau, P.K. Chan, M.H. Ng, J.J. Sung, R.S. Wong, ABO blood group and susceptibility to severe acute respiratory syndrome, JAMA 293 (12) (2005) 1450–1451.

[16] P. Guillon, M. Clément, V. Sébille, J.G. Rivain, C.F. Chou, N. Ruvoën-Cloquet, J. Le Pendu, Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies, Glycobiology 18 (12) (2008) 1085–1093.